Vivtex’s technology uses AI and high throughput screening to identify the combinations of drug ingredients that can deliver peptides through gastrointestinal tissue. Besides Novo Nordisk, the MIT spinout’s partners include Astellas Pharma, Equillium, and Orbis Medicines.
The post Novo Nordisk Commits Up to $2B to Drug Delivery Startup Vivtex for R&D of Oral Metabolic Meds appeared first on MedCity News.
